Syrhatech Completes A CHF 4.5 Million Financing Round
Share this article
Syrhatech, a French-Swiss CDMO innovating in the development and manufacture of injectable medical devices based in particular on hyaluronic acid, announces the closing of an investment of CHF 4.5 million, completed with strategic investors.
Funding for innovation and industrial capacity
This investment will enable Syrhatech to strengthen its R&D team at its site in Geneva, and to deploy a new production capacity at its plant in Chambéry, France, in order to meet the growing demand of the market for injectable medical devices based on hyaluronic acid, particularly for aesthetic dermatology but also for orthopaedics and ophthalmology. Other medical specialities should follow.
“This fundraising marks a key milestone for Syrhatech. It allows us to accelerate our development, strengthen our innovation in hyaluronic acid-based injectable products and increase our production capacity to support the growth of our partners,” says Gilles Bos, CEO of Syrhatech.
About Syrhatech
Syrhatech is a French-Swiss CDMO specializing in the development and production of injectable products based on hyaluronic acid and other biopolymers. With 30 years of experience, the company supports its partners in the R&D, formulation and manufacture of safe and innovative injectable products, primarily marketed as medical devices.
Source: Syrhatech | 
Syrhatech